Product Images Imatinib Mesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Imatinib Mesylate NDC 67877-634 by Ascend Laboratories, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

imatinib-bottle-100mg - imatinib bottle 100mg

imatinib-bottle-100mg - imatinib bottle 100mg

Each tablet contains 100 mg of imatinib free base. The usual dosage should be seen in the package insert. It should be stored between 15-30°C (59-86°F) with excursions permitted up to 25°C (77°F). It must be protected from moisture and dispensed in a tight container. This drug must be kept out of the reach of children. The information provided seems to be related to a drug sold in the form of 90 tablets distributed by "Ascend Laboratories, LLC ASC Parsany M) 07054 ASCEND am", with a code "TSDRUGSIEO1S".*

imatinib-bottle-400mg - imatinib bottle 400mg

imatinib-bottle-400mg - imatinib bottle 400mg

Each tablet of this medication contains 400mg of imatinib. It comes in a package with Potieny NDC 67877-634-3. The usual dosage must be referred to the package insert. The medication should be kept at 25°C (77°F), with excursions allowed to 15-30°C (59-86°F), and should be protected from moisture. The medication should be dispensed in a tight container with a USP Controlled Room Temperature. The medication must be kept away from children, and it is only available through prescription (Rx Only). It is manufactured in India by Shilpa Medicare Limited, Jadcherla - 509 301, and distributed by Ascend Laboratories, LLC, Parsippany, NJ 07054.*

imatinib-fig1 - imatinib fig1

imatinib-fig1 - imatinib fig1

This is a figure displaying the progression-free survival for a clinical trial population. It includes hazard ratio, log-rank test, and time in months since randomization. The percentage of participants without progression is also displayed.*

imatinib-fig2 - imatinib fig2

imatinib-fig2 - imatinib fig2

The figure shows the time to progression to AP or BC for patients receiving Imatinib mesate and PNeARRC. The number of patients, hazae Raso, and Log-rank Test results are also provided. Patients were censored at discontinuation of treatment or last follow-up.*

imatinib-struc - imatinib struc

imatinib-struc - imatinib struc

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.